163 related articles for article (PubMed ID: 23033296)
21. 99mTc-HYNIC-TOC imaging in the evaluation of pancreatic masses which are potential neuroendocrine tumors.
Qiao Z; Zhang J; Jin X; Huo L; Zhu Z; Xing H; Li F
Clin Nucl Med; 2015 May; 40(5):397-400. PubMed ID: 25706799
[TBL] [Abstract][Full Text] [Related]
22. Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.
Czepczyński R; Parisella MG; Kosowicz J; Mikołajczak R; Ziemnicka K; Gryczyńska M; Sowiński J; Signore A
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1635-45. PubMed ID: 17530247
[TBL] [Abstract][Full Text] [Related]
23. Feasibility of a streamlined imaging protocol in technetium-99m-Tektrotyd somatostatin receptor SPECT/CT.
Al-Chalabi H; Cook A; Ellis C; Patel CN; Scarsbrook AF
Clin Radiol; 2018 Jun; 73(6):527-534. PubMed ID: 29397911
[TBL] [Abstract][Full Text] [Related]
24. Improved kit formulation for preparation of (99m)Tc-HYNIC-TOC: results of preliminary clinical evaluation in imaging patients with neuroendocrine tumors.
Korde A; Mallia M; Shinto A; Sarma HD; Samuel G; Banerjee S
Cancer Biother Radiopharm; 2014 Nov; 29(9):387-94. PubMed ID: 25379612
[TBL] [Abstract][Full Text] [Related]
25. Microcystic Serous Cystadenoma Masquerading as Pancreatic Neuroendocrine Tumor on 99m Tc-HYNIC-TOC SPECT/CT.
Cai W; Dong Y; Zhao T; Dong A; Zhao Q
Clin Nucl Med; 2024 Feb; 49(2):e87-e89. PubMed ID: 38048519
[TBL] [Abstract][Full Text] [Related]
26. Predictive Value of 99MTC-hynic-toc Scintigraphy in Lung Neuroendocrine Tumor Diagnosis.
Boutsikou E; Porpodis K; Chatzipavlidou V; Hardavella G; Gerasimou G; Domvri K; Papadopoulos N; Avramidou V; Spyratos D; Kontakiotis T; Zarogoulidis K
Technol Cancer Res Treat; 2019 Jan; 18():1533033819842586. PubMed ID: 31079574
[TBL] [Abstract][Full Text] [Related]
27.
Briganti V; Cuccurullo V; Berti V; Di Stasio GD; Linguanti F; Mungai F; Mansi L
Curr Radiopharm; 2020; 13(3):166-176. PubMed ID: 31886756
[TBL] [Abstract][Full Text] [Related]
28. Role of 99mTc-HYNIC-Tyr3-octreotide scintigraphy in neuroendocrine tumors based on localization of the primary tumor.
Jimenez Londoño GA; García Vicente AM; Soriano Castrejon AM; Gómez López OV; Palomar Muñoz A; Vega Caicedo CH; Cordero García JM
Minerva Endocrinol; 2016 Mar; 41(1):10-8. PubMed ID: 25582872
[TBL] [Abstract][Full Text] [Related]
29. The utility of 99mTc-EDDA/HYNIC-TOC scintigraphy for assessment of lung lesions in patients with neuroendocrine tumors.
Pavlovic S; Artiko V; Sobic-Saranovic D; Damjanovic S; Popovic B; Jakovic R; Petrasinovic Z; Jaksic E; Todorovic-Tirnanic M; Saranovic D; Micev M; Novosel S; Nikolic N; Obradovic V
Neoplasma; 2010; 57(1):68-73. PubMed ID: 19895175
[TBL] [Abstract][Full Text] [Related]
30. Studies on batch formulation of a freeze dried kit for the preparation of
Mukherjee A; Korde A; Shinto A; Sarma HD; Kamaleswaran K; Dash A
Appl Radiat Isot; 2019 Mar; 145():180-186. PubMed ID: 30639635
[TBL] [Abstract][Full Text] [Related]
31.
Liepe K; Becker A
World J Nucl Med; 2018; 17(3):151-156. PubMed ID: 30034278
[TBL] [Abstract][Full Text] [Related]
32. [Preliminary clinical application of 99Tcm-HYNIC-TOC imaging in somatostatin receptor-positive tumors].
Li F; Chen LB; Jing HL; Du YR; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):563-6. PubMed ID: 14650159
[TBL] [Abstract][Full Text] [Related]
33. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
[TBL] [Abstract][Full Text] [Related]
34. Contribution of (99m)Tc-depreotide (Neospect) scintigraphy in lung cancer staging.
Karathanos E; Datseris I; Vlontzou E; Zisimopoulos A; Georgiou E
J BUON; 2010; 15(1):147-52. PubMed ID: 20414943
[TBL] [Abstract][Full Text] [Related]
35. (99m)Tc-HYNIC-TOC scintigraphy in evaluation of active Graves' ophthalmopathy (GO).
Sun H; Jiang XF; Wang S; Chen HY; Sun J; Li PY; Ning G; Zhao YJ
Endocrine; 2007 Jun; 31(3):305-10. PubMed ID: 17906380
[TBL] [Abstract][Full Text] [Related]
36. Two peptide receptor ligands (99m)Tc-EDDA/HYNIC-Tyr(3)-octreotide and (99m)Tc-EDDA/HYNIC-(D)Glu-octagastrin for scintigraphy of medullary thyroid carcinoma.
Kosowicz J; Mikołajczak R; Czepczyński R; Ziemnicka K; Gryczyńska M; Sowiński J
Cancer Biother Radiopharm; 2007 Oct; 22(5):613-28. PubMed ID: 17979564
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours.
Rodrigues M; Traub-Weidinger T; Li S; Ibi B; Virgolini I
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):532-40. PubMed ID: 16491425
[TBL] [Abstract][Full Text] [Related]
38. 99mTc-tektrotyd SPECT/MRI in the diagnosis of a gastroenteropancreatic neuroendocrine tumor.
Zandieh S; Gambini JP; Haller J; Rodrigues M
Clin Nucl Med; 2012 Apr; 37(4):e84-5. PubMed ID: 22391730
[No Abstract] [Full Text] [Related]
39. Comparison of 99mTc-HYNIC-TOC and HYNIC-TATE octreotide scintigraphy with FDG PET and 99mTc-MIBI in local recurrent or distant metastatic thyroid cancers.
Sager S; Kabasakal L; Halac M; Maecke H; Uslu L; Önsel Ç; Kanmaz B
Clin Nucl Med; 2013 May; 38(5):321-5. PubMed ID: 23531772
[TBL] [Abstract][Full Text] [Related]
40. Sister Mary Joseph Nodules on 99mTc HYNIC-TOC scintigraphy in patients with neuroendocrine tumors.
Jing H; Zhang Y; Li F
Clin Nucl Med; 2015 Feb; 40(2):166-8. PubMed ID: 25140559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
